Full-Time
Confirmed live in the last 24 hours
Contract development and manufacturing for pharmaceuticals
Expert
Bend, OR, USA
The job is onsite in Bend, Oregon.
You match the following Serán BioScience's candidate preferences
Employers are more likely to interview you if you match these preferences:
Serán Bioscience specializes in providing drug development and manufacturing services as a Contract Development and Manufacturing Organization (CDMO). They offer a variety of services, including preformulation, formulation development, dosage form development, spray drying, and particle engineering. Their operations adhere to current Good Manufacturing Practice (cGMP) standards, ensuring high quality and safety in their products through rigorous analytical quality control. Serán Bioscience serves a wide range of clients, from small biotech startups to large pharmaceutical companies, and is distinguished by its flexibility in tailoring services to meet specific client needs. The company's goal is to enhance the efficiency and effectiveness of drug development processes for their clients, ultimately leading to successful outcomes.
Company Size
51-200
Company Stage
Growth Equity (Venture Capital)
Total Funding
$194.5M
Headquarters
Bend, Oregon
Founded
2016
Help us improve and share your feedback! Did you find this helpful?
Paid Vacation
401(k) Retirement Plan
Health Insurance
Life Insurance
Disability Insurance
Mental Health Support
Pet Insurance
Serán Bioscience announces $200 million strategic growth transaction and plans for new commercial facility.
With over 200 team members, including 150 scientists and engineers, Serán plans to add 150 more employees as part of its expansion.
Serán Bioscience, a contract development and manufacturing organization (CDMO) providing a comprehensive suite of development, analytical, and manufacturing services to pharmaceutical and biotechnology companies, has announced a strategic growth transaction of more than $200 million, which will support Serán's continued growth and construction of a new commercial-scale manufacturing facility.
"Politics, Patients, and Pharma" Image Credit: Nicole Bean for BioSpaceWhen prescription drug benefits were added to Medicare via the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, the government was not given the ability to negotiate drug pricing. As a result, pharmaceutical companies were, and are, able to determine their own pricing. Another result is that prices for prescription drugs are higher in the U.S., significantly higher, than in most other developed countries.In a 2021 study conducted by the RAND Corporation, researchers estimated that U.S. drug prices were an average 2.56 times higher than the other 32 countries in the Organization for Economic Co-operation and Development (OECD). The gap increases to 3.44 times higher for larger brand-name drugs.Balancing Innovation, Pricing PatientsBoth the government and the pharma industry seek to give patients access to medications that enhance their quality of life. The question is how to achieve this without putting financial burdens on these patients
Serán is partnering with Oregon Bioscience Association ( oregonbio.org ) to establish a state-sponsored apprenticeship program with the goal of providing paid employment and education to entry-level operations and laboratory technicians.